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Abstract The incidence of heart failure and renal failure
is increasing and is associated with poor prognosis.
Moreover, these conditions do often coexist and this
coexistence results in worsened outcome. Various mecha-
nisms have been proposed as an explanation of this inter-
relation, including changes in hemodynamics, endothelial
dysfunction, inﬂammation, activation of renin-angiotensin-
aldosterone system, and/or sympathetic nervous system.
However, the exact mechanisms initializing and main-
taining this interaction are still unknown. In many experi-
mental studies on cardiac or renal dysfunction, the function
of the other organ was either not addressed or the authors
failed to show any decline in its function despite histo-
logical changes. There are few studies in which the dys-
function of both heart and kidney function has been
described. In this review, we discuss animal models of
combined cardiorenal dysfunction. We show that transla-
tion of the results from animal studies is limited, and there
is a need for new and better models of the cardiorenal
interaction to improve our understanding of this syndrome.
Finally, we propose several requirements that a new animal
model should meet to serve as a tool for studies on the
cardiorenal syndrome.
Keywords Cardiorenal syndrome  Heart-kidney
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Introduction
Recent observations from clinical trials have enhanced the
interest in the interaction between heart and kidney. Renal
dysfunction has been shown an independent risk factor for
the development of cardiovascular (CV) diseases [1, 2] and
is associated with worsened outcome in patients with
hypertension [3], post myocardial infarction (MI) [4, 5],
and a broad spectrum of patients with left ventricular
dysfunction [6, 7]. Moreover, in chronic renal failure, CV
morbidities are the main cause of mortality. Conversely,
cardiac dysfunction, for instance post-MI, leads to a
gradual decrease in renal function as reﬂected by an
increase in creatinine levels [8]. This interaction between
heart and kidney, where dysfunction of either one of them
leads to disorder of the other, is usually referred to as the
cardiorenal syndrome. It has been proposed that mecha-
nisms of this organ crosstalk include various changes in
hemodynamics, dysregulation of salt and ﬂuid balance,
endothelial dysfunction, inﬂammation, and activation of
regulatory systems such as the renin-angiotensin-aldoster-
one system (RAAS), and sympathetic nervous system
(SNS) [9, 10]. The described alterations may disturb other
factors and lead to a vicious circle, resulting in further
structural and functional damage in heart and/or kidney.
Commonly used drugs such as RAAS blockers or beta-
blockers may affect not only the targeted system, but may
also cause, via feedback loops or compensatory
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cardiorenal interaction. However, the exact pathophysio-
logical mechanisms behind the cardiorenal syndrome still
remain unclear. The design of most clinical studies on the
cardiorenal interaction does not allow drawing conclusions
and explanations for the heart-kidney interaction. Alter-
natively, this may be achieved by well-designed animal
studies. Many animal studies on cardiac or renal dysfunc-
tion have been performed and described in literature.
However, the authors either did not address the function of
the other organ of interest or the models they used did not
mimic the characteristics of the clinical cardiorenal syn-
drome. There are also few animal models described, which
combine cardiac and renal dysfunction. The objective of
this review is to discuss these combined animal models
used in studies on cardiorenal interaction. To this purpose,
we will brieﬂy describe the main pathophysiological
characteristics of chronic cardiorenal failure and then dis-
cuss the available animal models. Because an adequate
animal model would be instrumental for better under-
standing of this important clinical condition, we also dis-
cuss the need for a new model and characteristics of a new
model, which would help to study the pathophysiology of
the cardiorenal syndrome.
Pathophysiology of the cardiorenal interaction
Cardiorenal interaction is usually deﬁned as a disorder of
heart and kidney where dysfunction of one of the organs
induces disorder of the other. Several pathophysiological
mechanisms have been proposed to underlie the interaction
between heart and kidney in the cardiorenal syndrome [9–
12]. Guyton [13] described a model of complex hemody-
namic connections between heart and kidney. Bongartz
et al. [9] proposed a model based on Guyton’s model and
extended it by 4 cardiorenal connectors responsible for the
progression of the cardiorenal syndrome: the RAAS, the
SNS, inﬂammation, and nitric oxide/reactive oxygen spe-
cies (ROS) balance. Hemodynamic changes are considered
the main driving force in the pathophysiology of the car-
diorenal syndrome. If the failing heart cannot maintain
cardiac output, this results in reduction in perfusion of
peripheral organs [11], including decrease in renal blood
ﬂow (RBF). Decreased renal perfusion has been shown the
main determinant of reduced glomerular ﬁltration rate
(GFR) in heart failure patients [14]. Recent publications
have shown that GFR reduction in heart failure patients is
also inversely related to central venous pressure (CVP). In
the ESCAPE trial, the only hemodynamic parameter
associated with renal insufﬁciency was right atrial pressure
[15], suggesting an important role of (renal) congestion.
Increased CVP in the situation of unchanged systemic
arterial pressure leads to decrease in pressure gradient
across the glomeruli and subsequent decrease in RBF, but
also to increased hydrostatic pressure in the kidney and
subsequently to hypoxia and/or activation of intrarenal
RAAS. It has been suggested that the contribution of CVP
to kidney dysfunction is independent of cardiac output;
however, it occurs only when forward failure is present
[16]. The relationship between CVP and GFR seems to be
bidirectional, as impairment in renal function may lead to
salt and water retention and thus to increased venous
pressures [17].
Hemodynamic changes in heart failure activate multiple
regulatory mechanisms, among which the RAAS is the
most important system. Initially aimed to preserve cardiac
homeostasis, long-term activation of the RAAS eventually
leads to the progression of HF [17], myocardial remodeling
[18], and ﬁbrosis and necrosis in the myocardium [19].
Blocking RAAS reverses histological changes in the
myocardium, improves endothelial function, and reduces
adrenergic tone, resulting in improved prognosis. Less is
however known about the effects of long-term RAAS
inhibition on renal function in HF. It may help to preserve
GFR to some extent [20]; however, long-term RAAS
blockade substantially disables regulatory mechanisms of
the kidney [14].
Progression of heart failure leads also to compensatory
activation of baroreceptors and increase in sympathetic
activity. This on one hand preserves the cardiac output, but
has also adverse effects such as sympathetic overdrive,
cardiomyocyte apoptosis and necrosis, and arrhythmias on
the long term. Sympathetic activation has been also sug-
gested to have direct vascular effects on renal vasculature,
as renal sympathetic denervation may improve GFR [21].
Moreover, the activated SNS interacts with other cardio-
renal connectors, such as the RAAS [22, 23] and the oxi-
dative stress cascade [9].
There is growing evidence that one of the connectors of
the cardiorenal syndrome is oxidative stress. In heart failure
patients, increased oxidative stress has been demonstrated
[24] and impaired NO-mediated endothelial vasodilatation
has been related to reduction in renal perfusion [25]. Lower
availability of NO and increased production of ROS lead to
endothelial dysfunction that has been related to reduction in
renal perfusion [25], inﬂammation, and organ damage.
Inﬂammation is considered a risk factor for incidence of MI
and death in uremic patients [26] and a marker of severity
and progression of heart failure [27–30]. Moreover, inter-
action between oxidative stress, inﬂammation, and activa-
tion of RAAS has been reported [31, 32].
Another observed phenomenon of the relationship
between heart and renal failure is anemia [33]. Presence of
anemia has been shown to be associated with poor prog-
nosis in heart failure [34]. The pathogenesis of anemia in
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123heart failure seems to be multifactorial and to some extent
is a result of decreased renal function [35, 36]. The com-
bination of anemia and renal dysfunction in heart failure
patients is associated with much worse outcome suggesting
interaction between those two entities [37, 38]. Correction
of anemia improves cardiac performance in patients with
chronic kidney disease [39, 40] and both cardiac and renal
function in heart failure [41, 42].
The vicious circle of pathophysiological changes in
cardiorenal interaction leads to dysfunction of one or both
organs, accompanied by structural changes in both heart
and kidney. Pathological cardiac remodeling includes
changes in tissue architecture and myocyte/capillary ratio,
increased ﬁbrosis and apoptosis, and occurs not only in
response to cardiac, but also to renal stimuli. Presence of
albuminuria as a sign of glomerular injury has been shown
to be a strong predictor of CV outcome in the general
population [43] and in patients with hypertension [44].
However, the pathophysiology of albuminuria and its
relation with prognosis is unclear in heart failure. There is
also evidence that tubular damage is present in HF popu-
lation [45] and is associated with prognosis [46]. The
pathophysiological mechanisms underlying tubular damage
in heart failure are still unknown, but possible explanations
include regional hypoxia due to decreased RBF and
diuretic therapy.
Pathophysiological connections behind the cardiorenal
interactions are presented in Fig. 1, and the most important
clinical characteristics of this syndrome are summarized in
Table 1.
Animal models for cardiorenal interaction
Only a few animal models have been proposed so far as a
model for further studies on the cardiorenal syndrome in
which both cardiac and renal dysfunction have been
induced (Table 2). They are all based on the use of rodents.
Advantages of small animals include lower costs, avail-
ability, and housing conditions. There are multiple ways of
inducing cardiac dysfunction in rodent models. They
comprise of volume or pressure overload, myocardial
ischemia/infarction, administration of toxic agents, and
rapid ventricular pacing. The most commonly used tech-
nique of inducing cardiac dysfunction in studies on the
cardiorenal interaction is MI resulting from ligation of the
left coronary artery. Main advantages of this model are
Fig. 1 Pathophysiological
connections in the cardiorenal
syndrome (adapted from Bock
et al. [12])
Table 1 Pathophysiological characteristics of cardiorenal syndrome
Characteristics Clinical manifestation
Forward failure Decreased cardiac output
Reduced RBF
Backward failure Increased venous congestion
Neurohormonal activation Activation of RAAS
Activation of SNS
Oxidative stress Lower availability of nitric oxide
Increased production of ROS
Inﬂammation Circulating cytokines
Endothelial dysfunction
Anemia Low hemoglobin/hematocrit levels
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123simplicity, reproducibility, and its relation to human
pathophysiology. In this model, the cardiac output is sig-
niﬁcantly reduced 3–5 weeks after surgery [47] and the
impairment of left ventricular function is directly related to
the loss of myocardium [48]. Hemodynamic and neuro-
hormonal changes in this model resemble those of heart
failure observed in humans [49] and are also dependent on
the extent of cardiac damage [50–52]. The use of the MI
model has been essential in establishing the beneﬁcial
effects of RAAS blockade [53, 54], which were later
conﬁrmed in clinical trials, underscoring the agreement
between this model and human heart failure with respect to
the pathophysiology and treatment possibilities.
The most commonly used techniques of inducing renal
failure are based on the reduction of viable kidney tissue in
different ways. The main difference between them is the
extent of the removal and thus the degree of renal dys-
function they cause. Unilateral nephrectomy (UNX) leads
to mild renal function impairment without a substantial
increase in proteinuria or histological changes [55],
whereas subnephrectomy (SNX) leads to more severe renal
dysfunction and eventually to uremia and chronic kidney
disease complications similar as in humans [56, 57].
Changes in cardiac tissue architecture have also been
reported in subnephrectomized animals [58–60].
Van Dokkum et al. [55] have described a model of UNX
followed by MI 1 week later. They have shown an accel-
erated renal dysfunction in uninephrectomized rats when
combined with cardiac dysfunction. This has been evi-
denced by increased levels of proteinuria. Also more renal
damage, as measured by focal glomerulosclerosis, has been
reported in animals with combined cardiac and renal
Table 2 Rodent models of combined cardiorenal failure
Model References Cardiac changes Renal changes
UNX ? MI Van Dokkum et al. [55] Increased SBP
Decreased dP/dt max and dP/dt min
LVH
Increased plasma creatinine
Increased proteinuria
FGS
SNX ? MI Windt et al. [57] Increased SBP
Decreased dP/dt max and dP/dt min
LVH
Decreased capillary density
Decreased creatinine clearance
Decreased RBF
Increased proteinuria
FGS
Fibrosis
Dikow et al. [62] Increased SBP
Higher susceptibility to myocardial ischemia
Increased serum urea
Increased serum creatinine
Dikow et al. [56] Increased SBP
Decreased EF
Increased LVEDD
LVH
Fibrosis
Decreased capillary density
Increased serum urea
Increased serum creatinine
SNX ? L-NNA Bongartz et al. [66] Increased blood pressure
Decreased EF
Increased LVEDV
LVH
Fibrosis
Increased plasma creatinine
Increased plasma urea
Decreased creatinine clearance
Increased proteinuria
FGS
Tubulo-interstitial injury
Adriamycin Noiri et al. [70] LVH Increased plasma creatinine
Increased plasma urea
Decreased creatinine clearance
Fibrosis
Tubular damage
UNX uninephrectomy, SNX subnephrectomy, MI myocardial infarction, L-NNA Nx-nitro-L-arginine, SBP systolic blood pressure, dP/dt max
maximal rate of increase of left ventricular pressure, dP/dt min maximal rate of decrease of left ventricular pressure, LVH left ventricle
hypertrophy, RBF renal blood ﬂow, EF ejection fraction, LVEDD left ventricle end-diastolic diameter, LVEDV left ventricle end-diastolic
volume, FGS focal glomerulosclerosis
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123dysfunction. Creatinine levels were increased, as expected,
after nephrectomy; however, addition of MI did not lead to
further increase. Interestingly, the decrease in renal func-
tion was more pronounced in animals with large infarcts.
This might be due to the severity of cardiac dysfunction
and its effect on renal hemodynamics. It has been shown
that in rats after MI, the severity of ventricular dysfunction
and subsequent hemodynamic changes depend on infarct
size [48, 61] as well as time between intervention and
measurements [47, 52]. Decrease in cardiac function due to
small and moderate infarcts, results in either small or no
decrease in RBF [50–52]. When RBF is minimally
decreased, the animal upkeeps its GFR by a compensatory
increase in renal vascular resistance, like in humans [51].
More severe cardiac dysfunction as a result of large
infarction leads to a larger fall in RBF and a subsequent
decrease in GFR despite further increase in venous resis-
tance [51, 52]. However, the data on RBF in this model are
missing, and the only indication of more severe cardiac
dysfunction in the group with larger MI was more advanced
hypertrophy of the heart. No differences in brain natriuretic
peptide (BNP) levels, LV pressures nor contractility or
relaxation between groups have been reported. The blood
pressurewashigherintheanimalswithcombineddamagein
comparison with other experimental groups. This suggests
thatthecompensatedstageofheartfailurewasnotpresentin
this model. The more pronounced progression of cardiac
dysfunction due to the concomitant renal dysfunction has
also not been observed. However, it must be remembered
that the renal damage in this model was only mild, and there
was a short period of time between induction of renal and
cardiac damage. This might have resulted in limited effects
of renal dysfunction on heart tissue and its function.
The same group studied cardiorenal interaction in a
combined model with a more severe renal dysfunction,
introduced by means of SNX and 2 weeks later followed
by coronary ligation [57]. In this model, the SNX induced
proteinuria, decreased the creatinine clearance and
increased histological changes, such as focal glomerulo-
sclerosis, ﬁbrosis, and mesangial matrix expansion. Intro-
duction of the cardiac dysfunction on top of existing renal
dysfunction did not inﬂuence the levels of proteinuria nor
the histological changes, but led to decrease in creatinine
clearance and RBF. With regard to cardiac function,
combination of renal and cardiac function did not yield
additional effects, different from the effects of SNX or MI
alone. Animals with combined organ damage had high
blood pressure, similar to the animals with renal damage
alone, and decreased contractility and relaxation compa-
rable with the animals that underwent coronary ligation
only. Also, decrease in capillary density was the same as in
the MI alone group, showing no effect of preexisting renal
dysfunction on myocardium. This is somewhat in contrast
to literature ﬁndings that showed histological changes in
the myocardium of the subnephrectomized animals [58,
59]. However, again short period of time for the develop-
ment of renal dysfunction and lack of signs of severe
cardiac failure have to be considered. This model has also
been used in studies on the effects of RAAS inhibition on
the cardiorenal interaction. It has been shown that treat-
ment with lisinopril for 6 weeks prevented further histo-
logical changes in the kidney tissue or even reversed some
of them. Moreover, it restored the decreased RBF and
creatinine clearance levels. It also increased capillary
density and reversed the cardiac hypertrophy, proving the
beneﬁcial effects of this treatment and usefulness of this
model in studies on RAAS activation in the cardiorenal
syndrome.
A combined model of MI and SNX has been used by
Dikow et al. [62] to study cardiac histological changes as
an underlying mechanism of progression of cardiac disease
in cardiorenal interaction. In this study with transient cor-
onary ligation followed by reperfusion, it has been shown
that myocardium of the rats with renal dysfunction is more
susceptible to ischemia injury, which may explain the
higher death rate after MI in renal patients. Whereas the
total unperfused area was not different between animals
with and without renal dysfunction, which would be unli-
kely as it reﬂects the anatomy of the coronary vasculature
in the rat, the infarcted area was signiﬁcantly higher in
uremic animals. This effect was also present in animals
treated with antihypertensive treatment and low- and high-
salt diet, which excludes the underlying confounding
effects of hypertension, sympathetic overactivity, and salt
retention. The same group analyzed also the myocardial
remodeling in a model of more permanent MI [56]. They
have shown more advanced left ventricular remodeling in a
model with cardiorenal failure as documented by left
ventricular hypertrophy, decreased capillary density and
increased ﬁbrosis. Moreover, these changes were accom-
panied by decrease in cardiac function as assessed by
echocardiography. Interestingly, the presence of anemia
has also been reported in the animals with combined organ
damage. This could be of special interest, since anemia is
being considered one of the cardiorenal connectors [33, 63]
and beneﬁcial effects of treatment for anemia have been
shown in experimental studies. In MI heart failure model,
erythropoietin has been shown to improve cardiac function
and induce neovascularization [64]. On the other hand, in
subnephrectomized rats, anemia seemed to have protective
effect on kidney structure [65]; however, this effect has not
been investigated in a model with concomitant heart fail-
ure. Therefore, this model could also help to understand the
role of anemia in the cardiorenal syndrome.
Bongartz et al. [66] have recently developed a new
animal model of combined cardiorenal failure. This model
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123is based on the hypothesis that oxidative stress and the
dysbalance between nitric oxide (NO) and ROS are one of
the cardiorenal connectors [9, 63]. The inhibition of NO
synthase in rats has already been shown to cause hyper-
tension, cardiac dysfunction, and glomerular damage [67,
68]. In the MI model, oxidative stress has been proven to
decrease endothelial-dependent relaxation [50], whereas
antioxidant therapy prevents cardiac structure alterations
[69]. In the described model, renal dysfunction has been
induced by means of SNX, whereas cardiac dysfunction
was a result of NOS inhibition with Nx-nitro-L-arginine
(L-NNA). The combination of the above led to severe
cardiac dysfunction with increased blood pressure, end-
diastolic volume, and decreased ejection fraction. Signs of
congestion, increased cardiac ﬁbrosis, and myocyte
hypertrophy accompanied the functional changes. With
regard to the kidney function, the combination of SNX and
L-NNA resulted in increased plasma urea and creatinine
levels and proteinuria. However, only the latter was sig-
niﬁcantly higher than in animals with SNX alone. On the
histological level, combined cardiorenal damage was
characterized by increased FGS and tubulointerstitial
injury. Interestingly, the above changes had permanent
character and were not reversed even when treatment with
L-NNA was stopped. This model proves the importance of
oxidative stress in cardiorenal interaction and might serve
as a promising tool for further investigation of cardiorenal
connectors.
An alternative model, which does not require surgical
intervention, is the model of adriamycin-induced renal
damage. It has been shown that administration of adria-
mycin leads not only to deterioration of kidney function,
but heart function is also affected [70]. Both cardiac and
renal dysfunction resulting from adriamycin administration
are characterized by many features observed in humans
with cardiorenal failure—both on functional as well as on
the histological level [71–73]. However, the dose required
to induce the cardiac cardiomyopathy is much higher than
the one resulting in severe kidney dysfunction. Therefore,
the possibilities for investigation of dysfunction of both
organs at the same time are limited. Moreover, it is
important to mention that many of those changes are rather
the effect of the toxicity of adriamycin than involvement of
known cardiorenal connectors.
Discussion and future perspectives
In this review, we summarized the available data on animal
models used in the studies on cardiorenal interaction. The
choice of a proper model is crucial, because results
obtained in experimental studies may contribute to better
understanding of this important clinical syndrome and help
in establishing new treatment strategies. At this moment,
this translation is limited, because none of the models
described above entirely reproduce the pathophysiology
and characteristics of the cardiorenal syndrome observed in
humans. Therefore, there is a need for better models of
cardiorenal interaction that not only should mimic clinical
characteristics of this syndrome by cardiac, renal, hemo-
dynamic, and neurohumoral alterations, but also allow
evaluation of the effectiveness of treatment. Such a model
should consist of combined renal and cardiac injury char-
acterized by progressive deterioration of function of both
organs. With regard to the cardiac function, it should be
characterized by systolic dysfunction conﬁrmed by echo-
cardiography or hemodynamic measurements, resulting in
decrease in cardiac output and subsequent reduction in
RBF. Also, increased end-diastolic pressure and venous
congestion should be present in order to further investigate
latest ﬁndings from clinical observations. On the histolog-
ical level, cardiac injury should be characterized by
hypertrophy and ﬁbrosis and preferably with cardiomyo-
cyte/capillary mismatch. With regard to renal injury, such a
model should be characterized by a progressive decrease in
renal function reﬂected in increased levels of creatinine and
proteinuria or increased albumin excretion and decreased
GFR/creatinine clearance. The presence of glomeruloscle-
rosis and interstitial ﬁbrosis should be documented.
Important in developing a new model is to reduce the
function of both organs to such a degree that leads to
development of signiﬁcant dysfunction as well as to provide
enough time for its development. Both organ failures should
also preferably develop gradually to allow studies on
treatment for advanced stages as well as more preventive
treatment strategies. This can help in drawing conclusions
and give more insight into pathophysiology behind car-
diorenal interaction on different stages of its development.
There are multiple ways of inducing cardiac [74, 75] and
renal dysfunction [76] in rodents, which can be combined
for the development of a new model of cardiorenal inter-
action. They all have their advantages and drawbacks, and
none of them presents all the above-mentioned features of
the ideal model. Most of the models require surgery
intervention or administration of exogenous substances,
which already reduces their similarity to the clinical situ-
ation. Furthermore, the surgical interventions, such as MI
or reduction in kidney tissue, are performed on healthy
organs in a situation where the regulatory mechanisms are
not being activated. In humans, on the other hand, the
failure is usually preceded by gradual loss of the function
of chronically affected organs. The acute onset of the organ
failure substrate is one of the common drawbacks that limit
the clinical relevance of many popular models, such as
transverse aortic constriction. An important issue in the use
of animal models is also the severity of the induced organ
416 Heart Fail Rev (2012) 17:411–420
123failure. Moderate interventions result either in the devel-
opment of mild organ dysfunction or the organ failure will
develop only in a subset of the animals [48, 55, 75]. A more
severe approach leads to the development of overt organ
failure [48, 77], but results in high mortality rates [78] and
more acute onset of the heart failure substrate. This limits
the clinical relevance of such models. The usefulness of the
models based on surgical interventions is also limited by the
fact that they lead to signiﬁcant reduction in remaining
tissue mass, like in the SNX model or the MI model. This
reduces the potential target and the effects of treatment, as
well as possibilities for molecular analysis. Important to
remember is also that the differences in response to surgical
interventions have been reported between different genders
[79] or animal strains [80, 81]. Above-described drawbacks
of available animal models might question the possibility of
designing one perfect animal model of the cardiorenal
syndrome. However, it should be remembered that heart
and renal failure are heterogeneous disorders that result
from multiple underlying diseases and involve various
regulatory mechanisms. Due to the complexity of the
pathophysiology of heart and/or renal failure alone and in
combination, its proper understanding might as well require
the use of more than one animal model and the choice must
be made depending on the research question. The hetero-
geneous character and origin of cardiorenal failure require
also that all potential new models as well as the models
already known, including those described in this review,
should be studied in more detail. Not only well-established
cardiorenal connectors, but also new ﬁndings in the car-
diorenal interaction, such as increased venous congestion,
anemia, and tubular damage need further investigation and
should be addressed in these models. Only then, the use-
fulness of these models in studies on the cardiorenal syn-
drome can be evaluated.
Interesting alternative for the models described above
might be the use of genetic models of cardiac and renal
dysfunction. One of the biggest advantages of such models
is that they do not require surgery or pharmacological
intervention for induction of the disease. The onset of the
stimulus for organ failure is more gradual, which allows
studies on progression of the disease and prevention ther-
apy. Well-studied genetic models of heart failure are the
spontaneously hypertensive rat (SHR) [82] and the Dahl-
salt-sensitive rat [83]. However, both strains require long
time before they develop overt heart failure, which is their
main drawback. The Munich Wistar Fromter (MWF) rats
present many of the clinical characteristics of renal dys-
function [84]. However, again an extended period of time is
required for the development of the renal failure. Moreover,
some gender differences have been reported [85].
The genome of rodents has recently been well charac-
terized, which provides new opportunities in ﬁnding a new
better model for cardiorenal interaction. The ability of
genetic manipulation offers multiple possibilities for estab-
lishing new valuable models. Knocking out or overexpres-
sionofspeciﬁc genes orproteinsaswellastransgenesismay
lead to the development of new models of organ failure
[86–89]. This approach gives a good insight into role of a
given gene or protein in the pathophysiology of the disease.
Knock-out models can help also in understanding the path-
ophysiology of the diseases preceding the onset of organ
failure, such as atherosclerosis [90]. However, the genetic
manipulation does not allow control over the time of the
occurrence or the level of intervention. Change in the
expression of speciﬁc proteins may also inﬂuence their
biologicalpropertiesandfunction[91]aswellasactivatethe
compensatory mechanisms at very early stages.
Conclusion
There are only few animal models proposed for further
studies on the cardiorenal syndrome. They all represent to
someextentclinicalcharacteristicsofthissyndromeandwere
used in experimental studies to better understand the patho-
physiological connections between kidney and the heart.
However, the heterogeneous character of heart and renal
failure in humans limits the possibilities of complete repro-
duction of this syndrome in an animal model. Moreover, the
inductionoftheorgansfailureinanimalshasusuallyanacute
character, whereas heart and/or kidney dysfunction in
humansusuallydevelopoveryears.Therecentdevelopments
in molecular techniques provide promising possibilities of
developinganewanimalmodel,whichcouldbeusedasatool
for better understanding of the pathophysiology and treat-
ment targets in the cardiorenal syndrome.
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